> 首页 > 产品 > 一抗 > 其他 > Anti-LRP6 Reference Antibody (Novartis patent anti-LRP6)

Anti-LRP6 Reference Antibody (Novartis patent anti-LRP6)

Anti-LRP6 Reference Antibody (Novartis patent anti-LRP6) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-LRP6 Reference Antibody (Novartis patent anti-LRP6) is 100%, determined by SEC-HPLC.
PA-1 cells were stained with Novartis patent anti-LRP6 and negative control protein respectively, washed and then followed by PE and analyzed with FACS, with the EC50 is 0.044 nM.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	O75581
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-LALA-REM
Calculated MW	180429 Da

Additional Information
Target/Specificity	LRP6
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	LRP6
Function	Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalosomes (PubMed:11357136, PubMed:11448771, PubMed:15778503, PubMed:16341017, PubMed:16513652, PubMed:17326769, PubMed:17400545, PubMed:19107203, PubMed:19293931, PubMed:19801552, PubMed:28341812, PubMed:34896607). Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in various processes including retinal angiogenesis and bone formation (PubMed:11357136, PubMed:11448771, PubMed:15778503, PubMed:16341017, PubMed:16513652, PubMed:17326769, PubMed:17400545, PubMed:19107203, PubMed:19293931, PubMed:19801552, PubMed:28341812, PubMed:34896607). The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalosomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin (PubMed:16513652). Required for posterior patterning of the epiblast during gastrulation (By similarity).
Cellular Location	Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum. Membrane raft. Note=On Wnt signaling, undergoes a cycle of caveolin- or clathrin-mediated endocytosis and plasma membrane location. Released from the endoplasmic reticulum on palmitoylation Mono-ubiquitination retains it in the endoplasmic reticulum in the absence of palmitoylation. On Wnt signaling, phosphorylated, aggregates and colocalizes with AXIN1 and GSK3B at the plasma membrane in LRP6- signalosomes (By similarity). Chaperoned to the plasma membrane by HSP90B1 and MESD (PubMed:23572575). {ECO:0000250\|UniProtKB:O88572, ECO:0000269\|PubMed:23572575}
Tissue Location	Widely coexpressed with LRP5 during embryogenesis and in adult tissues